Pipeline

TheraVectys develops lentiviral vectors to prevent and treat cancer and infectious diseases,
both for human and veterinary indications.

EMERGING DISEASES PROGRAM

SARS-CoV-2- & PAN CORONAVIRUSES T-CELL VACCINE ARE TOP PRIORITIES SINCE FEB, 2020

Terms of Use
Privacy Policy
Cookies policy

Manage Consent

We use cookies to optimize our website and our service.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Préférences Préférences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Preferences

{title} {title} {title}

Pipeline

TheraVectys develops lentiviral vectors to prevent and treat cancer and infectious diseases,both for human and ​veterinary indications.

EMERGING DISEASES PROGRAM

SARS-CoV-2- & PAN CORONAVIRUSES T-CELL VACCINE ARE TOP PRIORITIES SINCE FEB, 2020

TheraVectys develops lentiviral vectors to prevent and treat cancer and infectious diseases,
both for human and veterinary indications.